U.S. flag

An official website of the United States government, Department of Justice.

NCJRS Virtual Library

The Virtual Library houses over 235,000 criminal justice resources, including all known OJP works.
Click here to search the NCJRS Virtual Library

Assessing the Detectability of Cannabinoid Analogs (Delta-8 THC, Delta-10 THC and CBD) and their Major Metabolites in Six Commercial Cannabinoid Urine Screening Kits

NCJ Number
308105
Author(s)
Ashley A. Pokhai
Date Published
2022
Length
39 pages
Annotation

This study assessed detectability of cannabinoid analogs in six urine screening kits.

Abstract

To evaluate the ability of six commercially available homogeneous urine cannabinoid screening kits to detect ∆8-THC, CBD and their major metabolites, and ∆10-THC chiral analogs at 50 ng/mL and 20 or 25 ng/mL cutoff concentrations. Six urine immunoassay kits (Abbott Cannabinoids – Abbott Diagnostics, LZI Cannabinoids (cTHC) Enzyme Immunoassay – Lin-Zhi International, DRI® Cannabinoid Assay and CEDIA™ THC – Thermo Fisher Scientific, ONLINE DAT Cannabinoid II – Roche Diagnostics, and Syva EMIT®II Plus – Siemens Healthineers) were evaluated at two different cutoff concentrations: 50 ng/mL and 20 or 25 ng/mL. The six commercially available homogeneous urine cannabinoid screening kits were able to detect ∆8-THC, 11-OH-∆8-THC, 11-COOH-∆8-THC, 6-OH-CBD, 7-OH-CBD, all ∆10-THC chiral analogs, and olivetol with varying selectivity depending on the screening kit. The kits were not able to detect CBD, 7-COOH-CBD, Abn-CBD, CBDA-A, and olivetolic acid. The analysis was performed on an Abbott Architect Plus c4000 (Abbott Diagnostics). ∆8-THC, CBD, olivetol and their major metabolites, and ∆10-THC chiral analogs were evaluated. (Published Abstract Provided)